FDA Actions vs Clinical Trials
Side-by-side coverage analysis for FDA Actions and Clinical Trials.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 20
- Avg Impact
- 7/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
Clinical Trials
Phase I-III results, trial design
- Stories
- 20
- Avg Impact
- 6.7/10
- Dominant Tone
- Bullish
- Latest
- 3d ago
Recent Headlines
FDA Actions
- Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
- Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
- Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
- Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
- Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
- HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
- AIIMS Recruits 460+ Researchers, Supercharging India’s Biomedical Pipeline
- First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status
- Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions
- $6.5B Fraud Sweep Nabs Genetic Testing Scams: Biotech’s Compliance Wake-Up Call
Clinical Trials
- 181 NCI Grants Worth $317M Canceled, Halting Cancer Trials
- NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender
- CaringAI Study Validates AI Cognitive Screening with 80% Clinician Concordance
- Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention
- Lexaria Doses 11-Arm GLP-1 Rat Study; Targets $100B Oral Market with Patent Offensive
- Cogent’s CGT1145 Hits 100x JAK2 Selectivity, IND Filing Next for Rare Cancer Drug
- HanchorBio Broadens HCB101 via InxMed Pact, Testing 2 Agents Beyond Gastric Cancer
- Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction
- Ebola Bundibugyo Outbreak Hits 1,830 Cases: No Approved Vaccine, Trials Underway
- $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts